The FDA has approved Cyramza (ramucirumab; Lilly) for use as a single agent in the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400ng/mL and have been treated with sorafenib.
The AGA present an updated summary of best practice advice for surveillance of hepatocellular cancer and DAA therapy timing.
This first-in-human trial will enroll up to 24 patients.
Fewer chemotherapy cycles could decrease long-term morbidity for certain patients.
There were more than 30,000 deaths due to liver cancer in the US during 2018.
The impact of direct-acting antiviral therapy was investigated in a large cohort of patients in complete remission following treatment of hepatitis C-related HCC.
Cabozantinib prolonged survival in relapsed HCC across a range of AFP levels, but a larger treatment benefit was observed with higher baseline AFP.
Sustained response duration, as opposed to complete or partial response, may be a better predictor of overall survival in HCC following cTACE.
The FDA based its approval on data from the REFLECT phase 3 study in which investigators enrolled 954 previously untreated patients with metastatic or unresectable hepatocellular carcinoma.
Twenty-three systemic therapy-naive patients with advanced hepatocellular carcinoma received atezolizumab plus bevacizumab every 3 weeks.
